Cullinan Therapeutics Inc (CGEM)

$14.43 +0.49 (3.52%)
Market Cap 873.39M
Revenue (ttm) 0.00
Net Income (ttm) -219.88M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,149,600
Avg Vol 828,842
Day's Range N/A - N/A
Shares Out 60.53M
Stochastic %K 84%
Beta -0.12
Analysts Strong Sell
Price Target $99.64

Company Profile

Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049, a FLT3xCD3 bispecific T cell engager, which is in Phase 1 clinical trials in patients with relapsed...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 410 4650
Address:
One Main Street, Suite 1350, Cambridge, United States
SuperGreenToday
SuperGreenToday Mar. 31 at 3:34 PM
$CGEM Share Price: $14.09 Contract Selected: Oct 16, 2026 $15 Calls Buy Zone: $1.70 – $2.10 Target Zone: $3.11 – $3.80 Potential Upside: 73% ROI Time to Expiration: 198 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
MoonAssassin
MoonAssassin Mar. 29 at 11:09 PM
$CGEM $CRDF $WTI $ABTC watchlist 5
1 · Reply
FreddieMercury91
FreddieMercury91 Mar. 27 at 7:33 PM
$CGEM fallen knife, another call by me
0 · Reply
Otha_X
Otha_X Mar. 27 at 5:30 PM
$CGEM $GILD
0 · Reply
FreddieMercury91
FreddieMercury91 Mar. 27 at 4:19 PM
$CGEM falling knife. news today, Vanguard disaccosiates itself from Culligan, had snd has no interest in CGEM
0 · Reply
FreddieMercury91
FreddieMercury91 Mar. 27 at 2:50 PM
$CGEM out of this pos lost a hundred bucks, scam city
0 · Reply
FreddieMercury91
FreddieMercury91 Mar. 27 at 1:39 PM
$CGEM scam stock in whats app group
0 · Reply
SirBensonbot
SirBensonbot Mar. 26 at 2:17 AM
$CGEM long
0 · Reply
notreload_ai
notreload_ai Mar. 24 at 9:22 PM
$GILD up to $2.2B acquisition of Ouro Medicines highlights strong potential for $CGEM velinotamig. Clear Street maintains Buy rating with $33 PT. https://notreload.xyz/gilead-deal-validates-cullinan-bcma-drug/
0 · Reply
outlawinvestor1
outlawinvestor1 Mar. 24 at 9:16 PM
$CGEM $GILD nice day, but still undervalued. look forward to cln978 readout.
0 · Reply
Latest News on CGEM
Cullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results

Mar 10, 2026, 7:00 AM EDT - 26 days ago

Cullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results

Cullinan Therapeutics to Participate in Upcoming Investor Conferences

Feb 24, 2026, 7:00 AM EST - 5 weeks ago

Cullinan Therapeutics to Participate in Upcoming Investor Conferences

Cullinan Therapeutics: Thesis Strengthening For This T-Cell Engager Specialist

Feb 23, 2026, 5:39 PM EST - 5 weeks ago

Cullinan Therapeutics: Thesis Strengthening For This T-Cell Engager Specialist

Cullinan Therapeutics, Inc. (CGEM) Presents at Citi's 2026 Virtual Oncology Leadership Summit Transcript

Feb 19, 2026, 4:05 PM EST - 6 weeks ago

Cullinan Therapeutics, Inc. (CGEM) Presents at Citi's 2026 Virtual Oncology Leadership Summit Transcript

Cullinan Therapeutics to Participate in Fireside Chat at the Citi 2026 Virtual Oncology Leadership Summit

Feb 18, 2026, 7:00 AM EST - 6 weeks ago

Cullinan Therapeutics to Participate in Fireside Chat at the Citi 2026 Virtual Oncology Leadership Summit

Cullinan Therapeutics to Participate in Fireside Chat at the Guggenheim Emerging Outlook: Biotech Summit 2026

Feb 5, 2026, 7:00 AM EST - 2 months ago

Cullinan Therapeutics to Participate in Fireside Chat at the Guggenheim Emerging Outlook: Biotech Summit 2026

Cullinan Therapeutics: Cash-Rich Biotech With Multiple Value Drivers

Jan 28, 2026, 11:03 PM EST - 2 months ago

Cullinan Therapeutics: Cash-Rich Biotech With Multiple Value Drivers

Cullinan Therapeutics Provides Corporate Update and Highlights Anticipated 2026 Milestones

Jan 8, 2026, 7:00 AM EST - 3 months ago

Cullinan Therapeutics Provides Corporate Update and Highlights Anticipated 2026 Milestones

Cullinan Therapeutics, Inc. (CGEM) Discusses Initial CLN-049 Results and Development Strategy for AML Applications Transcript

Dec 9, 2025, 4:37 AM EST - 4 months ago

Cullinan Therapeutics, Inc. (CGEM) Discusses Initial CLN-049 Results and Development Strategy for AML Applications Transcript

Cullinan Therapeutics Showcases Compelling Clinical Data in AML for CLN-049, Novel FLT3xCD3 T Cell Engager, in Oral Presentation at the 67th ASH Meeting

Dec 8, 2025, 10:31 AM EST - 4 months ago

Cullinan Therapeutics Showcases Compelling Clinical Data in AML for CLN-049, Novel FLT3xCD3 T Cell Engager, in Oral Presentation at the 67th ASH Meeting

Cullinan Therapeutics Receives FDA Fast Track Designation for CLN-049, a Novel FLT3xCD3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia

Dec 1, 2025, 7:00 AM EST - 4 months ago

Cullinan Therapeutics Receives FDA Fast Track Designation for CLN-049, a Novel FLT3xCD3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia

Taiho Oncology, Taiho Pharmaceutical and Cullinan Therapeutics Initiate Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Zipalertinib for Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

Nov 20, 2025, 7:00 AM EST - 4 months ago

Taiho Oncology, Taiho Pharmaceutical and Cullinan Therapeutics Initiate Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Zipalertinib for Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

Cullinan Therapeutics to Participate in Upcoming Investor Conferences and Host Analyst and Investor Event at 2025 ASH Annual Meeting

Nov 10, 2025, 7:00 AM EST - 5 months ago

Cullinan Therapeutics to Participate in Upcoming Investor Conferences and Host Analyst and Investor Event at 2025 ASH Annual Meeting

Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results

Nov 6, 2025, 7:00 AM EST - 5 months ago

Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results

Cullinan Therapeutics to Showcase New Data Demonstrating Compelling Clinical Activity for CLN-049, a Novel FLT3xCD3 T Cell Engager, in AML Patients in an Oral Presentation at the 67th ASH Annual Meeting

Nov 3, 2025, 9:11 AM EST - 5 months ago

Cullinan Therapeutics to Showcase New Data Demonstrating Compelling Clinical Activity for CLN-049, a Novel FLT3xCD3 T Cell Engager, in AML Patients in an Oral Presentation at the 67th ASH Annual Meeting

Cullinan Therapeutics Shares Additional Preclinical B Cell Depletion Data for CLN-978, Supporting Clinical Development Across Multiple Autoimmune Diseases, at ACR Convergence 2025

Oct 25, 2025, 11:01 AM EDT - 5 months ago

Cullinan Therapeutics Shares Additional Preclinical B Cell Depletion Data for CLN-978, Supporting Clinical Development Across Multiple Autoimmune Diseases, at ACR Convergence 2025

Cullinan Therapeutics: Worthy Of A Small Position

Oct 17, 2025, 7:01 AM EDT - 6 months ago

Cullinan Therapeutics: Worthy Of A Small Position

Cullinan Therapeutics Cancer Drug Shows Efficacy In Brain Metastases Among Lung Cancer Patients With Certain Mutations

Oct 13, 2025, 12:46 PM EDT - 6 months ago

Cullinan Therapeutics Cancer Drug Shows Efficacy In Brain Metastases Among Lung Cancer Patients With Certain Mutations

Taiho Oncology and Cullinan Therapeutics Present Data on Zipalertinib in Patients with NSCLC with EGFR mutations and Active Brain Metastases at the ESMO Congress 2025

Oct 12, 2025, 6:27 PM EDT - 6 months ago

Taiho Oncology and Cullinan Therapeutics Present Data on Zipalertinib in Patients with NSCLC with EGFR mutations and Active Brain Metastases at the ESMO Congress 2025

Cullinan Therapeutics to Participate in Fireside Chat at the Stifel 2025 Virtual Immunology and Inflammation Forum

Sep 12, 2025, 7:00 AM EDT - 7 months ago

Cullinan Therapeutics to Participate in Fireside Chat at the Stifel 2025 Virtual Immunology and Inflammation Forum

Cullinan Therapeutics, Inc. (CGEM) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 10, 2025, 10:50 AM EDT - 7 months ago

Cullinan Therapeutics, Inc. (CGEM) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Taiho Oncology and Cullinan Therapeutics Present Data on Zipalertinib at the IASLC 2025 World Conference on Lung Cancer

Sep 9, 2025, 5:30 AM EDT - 7 months ago

Taiho Oncology and Cullinan Therapeutics Present Data on Zipalertinib at the IASLC 2025 World Conference on Lung Cancer

Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results

Aug 7, 2025, 7:00 AM EDT - 8 months ago

Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results

Cullinan Therapeutics: Betting On Zipalertinib NDA Catalyst

Jul 15, 2025, 10:24 PM EDT - 9 months ago

Cullinan Therapeutics: Betting On Zipalertinib NDA Catalyst

Cullinan Therapeutics Licenses Rights to Velinotamig, a Clinical-Stage BCMA-Directed Bispecific T Cell Engager, from Genrix Bio for Development in Autoimmune Diseases

Jun 4, 2025, 4:02 PM EDT - 10 months ago

Cullinan Therapeutics Licenses Rights to Velinotamig, a Clinical-Stage BCMA-Directed Bispecific T Cell Engager, from Genrix Bio for Development in Autoimmune Diseases

Taiho Oncology and Cullinan Therapeutics Announce Pivotal REZILIENT1 Phase 1/2 Data Published in the Journal of Clinical Oncology

Jun 1, 2025, 8:21 AM EDT - 11 months ago

Taiho Oncology and Cullinan Therapeutics Announce Pivotal REZILIENT1 Phase 1/2 Data Published in the Journal of Clinical Oncology

Cullinan Therapeutics to Host Analyst and Investor Event at 2025 ASCO Annual Meeting and Participate in Jefferies 2025 Global Healthcare Conference

May 29, 2025, 7:00 AM EDT - 11 months ago

Cullinan Therapeutics to Host Analyst and Investor Event at 2025 ASCO Annual Meeting and Participate in Jefferies 2025 Global Healthcare Conference

Cullinan Therapeutics, Taiho Pharmaceutical, and Taiho Oncology to Present Positive Results from Pivotal Phase 2b REZILIENT1 Trial of Zipalertinib at ASCO 2025

May 22, 2025, 5:15 PM EDT - 11 months ago

Cullinan Therapeutics, Taiho Pharmaceutical, and Taiho Oncology to Present Positive Results from Pivotal Phase 2b REZILIENT1 Trial of Zipalertinib at ASCO 2025

Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results

May 8, 2025, 7:00 AM EDT - 11 months ago

Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results

Cullinan Therapeutics to Initiate Study of CLN-978, a Bispecific CD19 T Cell Engager Administered Subcutaneously, in Patients with Sjögren's Disease in the United States

Apr 29, 2025, 7:00 AM EDT - 1 year ago

Cullinan Therapeutics to Initiate Study of CLN-978, a Bispecific CD19 T Cell Engager Administered Subcutaneously, in Patients with Sjögren's Disease in the United States

Cullinan Therapeutics to Present Results from REZILIENT1, a Phase 1/2 Trial of Zipalertinib in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Have Received Prior Therapy, at ASCO 2025

Apr 23, 2025, 10:14 AM EDT - 1 year ago

Cullinan Therapeutics to Present Results from REZILIENT1, a Phase 1/2 Trial of Zipalertinib in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Have Received Prior Therapy, at ASCO 2025

Cullinan Therapeutics Receives Approval from European Medicines Agency to Initiate Phase 1 Trial of CLN-978, a Bispecific CD19 T Cell Engager Administered Subcutaneously, in Patients with Rheumatoid Arthritis

Apr 16, 2025, 7:00 AM EDT - 1 year ago

Cullinan Therapeutics Receives Approval from European Medicines Agency to Initiate Phase 1 Trial of CLN-978, a Bispecific CD19 T Cell Engager Administered Subcutaneously, in Patients with Rheumatoid Arthritis

Cullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 27, 2025, 7:00 AM EST - 1 year ago

Cullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Taiho Pharmaceutical, Taiho Oncology, and Cullinan Therapeutics Announce Primary Endpoint Met in Phase 2b Trial of Zipalertinib in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Have Received Prior Therapy

Jan 28, 2025, 7:00 PM EST - 1 year ago

Taiho Pharmaceutical, Taiho Oncology, and Cullinan Therapeutics Announce Primary Endpoint Met in Phase 2b Trial of Zipalertinib in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Have Received Prior Therapy

Cullinan Therapeutics' CLN-978 And Zipalertinib Look Promising In NSCLC

Jan 9, 2025, 11:11 PM EST - 1 year ago

Cullinan Therapeutics' CLN-978 And Zipalertinib Look Promising In NSCLC

Cullinan Therapeutics: Casting A Wide Net With Their Pipeline

Jan 8, 2025, 5:26 PM EST - 1 year ago

Cullinan Therapeutics: Casting A Wide Net With Their Pipeline

Cullinan Therapeutics Announces Preclinical Data for CLN-978, a CD19-directed T Cell Engager, to be Presented at ACR Convergence 2024

Nov 14, 2024, 10:01 AM EST - 1 year ago

Cullinan Therapeutics Announces Preclinical Data for CLN-978, a CD19-directed T Cell Engager, to be Presented at ACR Convergence 2024

Cullinan Therapeutics to Participate in Fireside Chat at Stifel 2024 Healthcare Conference

Nov 5, 2024, 7:00 AM EST - 1 year ago

Cullinan Therapeutics to Participate in Fireside Chat at Stifel 2024 Healthcare Conference

Cullinan Therapeutics to Present Preclinical Data for CLN-978, a CD19-directed T Cell Engager, at ACR Convergence 2024

Nov 4, 2024, 7:00 AM EST - 1 year ago

Cullinan Therapeutics to Present Preclinical Data for CLN-978, a CD19-directed T Cell Engager, at ACR Convergence 2024

Cullinan Therapeutics Receives U.S. FDA Clearance of Investigational New Drug Application for CLN-978 Administered Subcutaneously in Patients with Moderate to Severe Systemic Lupus Erythematosus

Oct 16, 2024, 7:00 AM EDT - 1 year ago

Cullinan Therapeutics Receives U.S. FDA Clearance of Investigational New Drug Application for CLN-978 Administered Subcutaneously in Patients with Moderate to Severe Systemic Lupus Erythematosus

Cullinan Therapeutics Receives Approval to Initiate its Global Phase 1 Clinical Trial of CLN-978 for the Treatment of Systemic Lupus Erythematosus

Sep 17, 2024, 7:00 AM EDT - 1 year ago

Cullinan Therapeutics Receives Approval to Initiate its Global Phase 1 Clinical Trial of CLN-978 for the Treatment of Systemic Lupus Erythematosus

Cullinan Therapeutics Presents Positive Updated Data from Module C of Zipalertinib Pivotal Phase 2b Study at ESMO 2024

Sep 14, 2024, 4:15 AM EDT - 1 year ago

Cullinan Therapeutics Presents Positive Updated Data from Module C of Zipalertinib Pivotal Phase 2b Study at ESMO 2024

Cullinan Therapeutics Announces Positive Initial Data from Pivotal Phase 2b REZILIENT1 Study of Zipalertinib

Jun 1, 2024, 7:00 AM EDT - 2 years ago

Cullinan Therapeutics Announces Positive Initial Data from Pivotal Phase 2b REZILIENT1 Study of Zipalertinib

Cullinan Therapeutics to Participate in Fireside Chat at TD Cowen 5th Annual Oncology Innovation Summit

May 24, 2024, 8:00 AM EDT - 2 years ago

Cullinan Therapeutics to Participate in Fireside Chat at TD Cowen 5th Annual Oncology Innovation Summit

Cullinan Therapeutics to Present First Data for CLN-619, a Novel Anti-MICA/B Antibody, in Combination with a Checkpoint Inhibitor and Updated Monotherapy Data at ASCO 2024

May 23, 2024, 5:04 PM EDT - 2 years ago

Cullinan Therapeutics to Present First Data for CLN-619, a Novel Anti-MICA/B Antibody, in Combination with a Checkpoint Inhibitor and Updated Monotherapy Data at ASCO 2024

Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results

May 15, 2024, 4:05 PM EDT - 2 years ago

Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results

Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial Officer

Apr 29, 2024, 7:00 AM EDT - 2 years ago

Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial Officer

Cullinan Therapeutics to Present Clinical Data from Phase 1 Study Evaluating Novel Anti-MICA/B Antibody, CLN-619, as Monotherapy and in Combination with a Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ASCO 2024

Apr 24, 2024, 10:09 AM EDT - 2 years ago

Cullinan Therapeutics to Present Clinical Data from Phase 1 Study Evaluating Novel Anti-MICA/B Antibody, CLN-619, as Monotherapy and in Combination with a Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ASCO 2024

Cullinan Therapeutics Announces Strategic Expansion into Autoimmune Diseases

Apr 16, 2024, 7:00 AM EDT - 2 years ago

Cullinan Therapeutics Announces Strategic Expansion into Autoimmune Diseases

Cullinan Therapeutics Announces Oversubscribed $280 million Private Placement

Apr 16, 2024, 6:59 AM EDT - 2 years ago

Cullinan Therapeutics Announces Oversubscribed $280 million Private Placement

SuperGreenToday
SuperGreenToday Mar. 31 at 3:34 PM
$CGEM Share Price: $14.09 Contract Selected: Oct 16, 2026 $15 Calls Buy Zone: $1.70 – $2.10 Target Zone: $3.11 – $3.80 Potential Upside: 73% ROI Time to Expiration: 198 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
MoonAssassin
MoonAssassin Mar. 29 at 11:09 PM
$CGEM $CRDF $WTI $ABTC watchlist 5
1 · Reply
FreddieMercury91
FreddieMercury91 Mar. 27 at 7:33 PM
$CGEM fallen knife, another call by me
0 · Reply
Otha_X
Otha_X Mar. 27 at 5:30 PM
$CGEM $GILD
0 · Reply
FreddieMercury91
FreddieMercury91 Mar. 27 at 4:19 PM
$CGEM falling knife. news today, Vanguard disaccosiates itself from Culligan, had snd has no interest in CGEM
0 · Reply
FreddieMercury91
FreddieMercury91 Mar. 27 at 2:50 PM
$CGEM out of this pos lost a hundred bucks, scam city
0 · Reply
FreddieMercury91
FreddieMercury91 Mar. 27 at 1:39 PM
$CGEM scam stock in whats app group
0 · Reply
SirBensonbot
SirBensonbot Mar. 26 at 2:17 AM
$CGEM long
0 · Reply
notreload_ai
notreload_ai Mar. 24 at 9:22 PM
$GILD up to $2.2B acquisition of Ouro Medicines highlights strong potential for $CGEM velinotamig. Clear Street maintains Buy rating with $33 PT. https://notreload.xyz/gilead-deal-validates-cullinan-bcma-drug/
0 · Reply
outlawinvestor1
outlawinvestor1 Mar. 24 at 9:16 PM
$CGEM $GILD nice day, but still undervalued. look forward to cln978 readout.
0 · Reply
JFais
JFais Mar. 24 at 7:21 PM
$CGEM- nice red to green today as the market digests $GILD $GLPG Ouro $1.6B buyout & readthrough to T-cell engager space on the whole
0 · Reply
JFais
JFais Mar. 24 at 7:19 PM
$CGEM nice red to green today as the market digests $GILD $GLPG Ouro $1.6B buyout & repercussions
0 · Reply
JFais
JFais Mar. 24 at 12:17 PM
$CGEM (L)
0 · Reply
Doom_Gloom_AR
Doom_Gloom_AR Mar. 24 at 1:23 AM
$CGEM Overpaid should of bought $CGEM cd-19>bmca https://www.businesswire.com/news/home/20260323998270/en/Gilead-Sciences-to-Acquire-Ouro-Medicines-to-Advance-First-in-Class-T-Cell-Engager-Program-for-Autoimmune-Diseases?utm_campaign=shareaholic&utm_medium=copy_link&utm_source=bookmark
0 · Reply
outlawinvestor1
outlawinvestor1 Mar. 23 at 9:11 PM
$CGEM ouros is worth $1.5B upfront to $GILD . cullinan's fully diluted market cap is $915M w/ $439M in cash. https://firstwordpharma.com/story/7145887
0 · Reply
CrispDry
CrispDry Mar. 23 at 4:42 PM
$CGEM did something happen? $XBI
1 · Reply
Nosh
Nosh Mar. 23 at 3:56 PM
$CGEM Added here...cost average still over $13 though. Working on it.
0 · Reply
aletz
aletz Mar. 12 at 1:47 PM
$CGEM https://www.biostockinfo.com/t-cell-engagers-tce-the-race-to-reset-the-immune-system-and-the-biotechs-positioning-to-win/ This article explains what TCE is about and how CGEM is preparing for the new trend
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Mar. 10 at 3:30 PM
$CGEM Q4 '25 Earnings Results & Recap Cullinan expects its current cash, cash equivalents, investments, and interest receivable of $377.9M and $61.1M, respectively, to fund operations into 2029, based on current operational plans.
0 · Reply
rain____
rain____ Mar. 9 at 2:24 AM
$CGEM .....................
0 · Reply
HighRegard
HighRegard Mar. 5 at 3:18 AM
$CGEM this is trending nicely with solid price targets from analusts and recetnly citi. Also off the radar from worlds tormoil and largely saw very little negativity affeting the wider market and larger caps. been in since $10 and will think about $30 partial exit ...bullish. Keep eyes on news coming out about continuing progress and potential
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Mar. 3 at 1:06 AM
$CGEM RSI: 85.74, MACD: 1.0101 Vol: 1.37, MA20: 13.15, MA50: 11.76 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply